Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival

Clinical Immunology

Volumn 133, Issue 3, 2009, Pages 333-352

  Dobrzanski, Mark J ^a   Rewers Felkins, Kathleen A ^a   Quinlin, Imelda S ^a   Samad, Khaliquzzaman A ^a   Phillips, Catherine A ^a,b   Robinson, William ^a,c   Dobrzanski, David J ^d   Wright, Stephen E ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Harrington Cancer Center   (United States)

^d Bristol Hospital   (United States)

Author keywords

Adoptive T cell immunotherapy; Chemokines; Regulatory T cells; T effector memory cells; Th1 effector cells; Tumor immunity

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MUCIN 1; PACLITAXEL; TRANSCRIPTION FACTOR FOXP3;

ABDOMINAL PAIN; ADOPTIVE TRANSFER; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOLYSIS; DISEASE FREE SURVIVAL; EFFECTOR CELL; EX VIVO STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFUSION; MEMORY T LYMPHOCYTE; MODULATION; MULTIPLE CYCLE TREATMENT; OCCLUSION; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; THERAPY EFFECT; TUMOR IMMUNITY;

AGED; AMINO ACID SEQUENCE; ANTIGENS, CD; ANTIGENS, CD45; CA-125 ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUCIN-1; OVARIAN NEOPLASMS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 70350586745     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.08.007     Document Type: Article

References (85)

1. Yee C., Thompson J.A., Bryd D., Ridell S.R., Roche P., Celis E., and Greenberg P.D. Adoptive T cell therapy using antigen-specific CD8 T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. 99 (2002) 16168-16176
2. Yee C., Thompson J.A., Roche P., Bryd D.R., Lee P.P., Piepkorn M., Kenyon K., Davis M.M., Riddell S.R., and Greenberg P.D. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. J. Exp. Med. 192 (2000) 1637-1643
3. Dudley M.E., Wunderlich J.R., Robbins J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., Robinson M.R., Raffeld M., Duray P., Seipp C.A., Rogers-Freezer L., Morton K.E., Mavroukakis S.A., White D.E., and Rosenberg S.A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002) 850-854
4. Meidenbauer N., Marienhagen J., Laumer M., Vogl S., Heymann J., Andreesen R., and Mackensen A. Survival and tumor localization of adoptively transferred melan-A-specific T cells in melanoma patients. J. Immunol. 170 (2003) 2161-2169
5. Hunder N.N., Wallen H., Cao J., Hendricks D.W., Reilly J.Z., Rodmyre R., Jungbluth A., Gnjatic S., Thompson J.A., and Yee C. Treatment of metastatic melanoma with autologous CD4 T cells against NY-ESO-1. N. Eng. J. Med. 358 (2008) 2698-2703
6. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., White D.E., Wunderlich J.R., Canevari S., Rogers-Freezer L., Chen C.C., Yang J.C., Rosenberg S.A., and Hwu P. A phase 1 study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12 (2006) 6106-6115
7. Rosenberg S.A., and Dudley M.E. Cancer regression in patients with metastatic melanoma after transfer of autologous antitumor lymphocytes. Proc. Natl. Acad. Sci. 101 (2004) 14639-14645
8. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., and Dudley M.E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8 (2008) 299-308
9. Yee C., and Greenberg P. Modulating T cell immunity to tumors: new strategies for monitoring T cell responses. Nature Rev. Cancer 2 (2002) 409-419
10. Mizoguchi H., O'Shea J.J., Longo D.L., Loeffler C.M., McVicar D.W., and Ochoa A.C. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258 (1992) 1795-1799
11. June C.H. Principles of adoptive T cell cancer therapy. J. Clin. Invest. 117 (2007) 1204-1212
12. Curiel T.J. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117 (2007) 1167-1174
13. Ossendorp F., Mengede E., Camps M., Filius R., and Melief C.J.M. Specific T helper cell requirements for optimal induction of CTL against MHC class II negative tumors. J. Exp. Med. 187 (1998) 693-702
14. Tham E.L., Shrikant P., and Mescher M.F. Activation-induced non-responsiveness: a Th-dependent regulatory checkpoint in the CTL response. J. Immunol. 168 (2002) 1190-1197
15. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., and White D.E. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86 (1994) 1159-1166
16. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Sznol M., Schwarz S.L., Spiess P.J., Wunderlich J.R., Seipp C.A., Einhorn J.H., Rogers-Freezer L., and White D.E. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163 (1999) 1690-1695
17. Robbins P.F., El-Gamil M., Li Y.F., Zeng G., Dudley M., and Rosenberg S.A. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor infiltrating lymphocytes from a patient with melanoma. J. Immunol. 169 (2002) 6036-6047
18. Hu H., Winter H., Urba W.J., and Fox B.A. Divergent roles for CD4 T cells in the priming and effector/memory phases of adoptive immunotherapy. J. Immunol. 165 (2000) 4246-4253
19. Hess S.D., Egilmez N.K., Bailey N., Anderson T.M., Mathiowitz E., Bernstein S.H., and Bankert R.B. Human CD4 T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-γ. J. Immunol. 170 (2003) 400-412
20. Hung K., Hayashi A., Lafond-Walker A., Lowenstein C., Pardoll D., and Lavitsky H. The central role of CD4 T cells in their antitumor immune response. J. Exp. Med. 12 (1998) 2357-2368
21. Tatsumi T., Kierstead L.S., Ranierri E., Gesualdo L., Schena F.P., Finke J.H., Bukowski R.M., Mueller-Berghaus J., Kirkwood J.M., Kwok W.W., and Storkus W.J. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4 T cell responses against MAGE-6 in HLA-DRB1 0401 patients with renal cell carcinoma or melanoma. J. Exp. Med. 196 (2002) 619-628
22. Mumberg D., Monarch P.A., Wandderling S., Philip M., Toledano A.Y., Schreiber R.D., and Schreiber H. CD4 T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. 96 (1999) 8633-8642
23. Dobrzanski M.J., Reome J.B., Hollenbaugh J.A., and Dutton R.W. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J. Immunol. 172 (2004) 1380-1391
24. Bacecher-Allan C., and Hafler D.A. Human regulatory T cells and their role in autoimmune disease. Immunol. Rev. 212 (2006) 203-216
25. Awwad M., and North R.J. Cyclophosphamide (CY)-facilitated adoptive immunotherapy of a CY-resistant tumor. Evidence that CY permits the expression of adoptive T cell-mediated immunity by removing suppressor T cells rather than by reducing tumor burden. Immunology 65 (1988) 87-92
26. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat. Rev. Immunol. 6 (2006) 295-307
27. Lizee G., Cantu M.A., and Hwu P. Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin. Cancer Res. 13 (2007) 5250-5255
28. Piccirillo C.A., and Shevach E.M. Naturally occurring CD4/CD25 immunoregulatory T cells: central players in the arena of peripheral tolerance. Sem. Immunol. 16 (2004) 81-88
29. Vignali D.A., Collison L.W., and Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 8 (2008) 523-532
30. Shevach E.M., Dipaolo M., Andersson J., Zhao D., Stephens G.L., and Thornton A.M. The lifestyle of naturally occurring CD4CD25Foxp3 regulatory T cells. Immunol. Rev. 212 (2006) 60-73
31. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burrow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Luckner A., Disis M.L., Knutson K.L., Chen W., and Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 10 (2004) 942-949
32. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., Deibl M., Gastl G., Gunsilius E., and Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11 (2005) 5380-8326
33. Singh A.P., Chauhan S.C., Bafna S., Johansson S.L., Smith L.M., Moniaux N., Lin M.F., and Batra S.K. Abberent expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate 66 (2006) 421-429
34. Baldus S.E., Wienand J.R., Werner J.P., Landsberg S., Drebber U., Hanisch F.G., and Dienes H.P. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int. J. Oncol. 27 (2005) 1289-1297
35. Vlad A.M., Kettel J.C., Alajez N.M., Carlos C.A., and Finn O.J. MUC1 immunobiology: from discovery to clinical application. Adv. Immunol. 82 (2004) 249-293
36. VanLith M.L., Kohlgraf K.G., Sivinski C.L., Tempero R.M., and Hollingsworth M.A. MUC1-specific antitumor responses: molecular requirements for CD4-mediated responses. Int. Immunol. 14 (2002) 873-882
37. Pecher G., Haring A., Kaiser L., and Thiel E. Mucin gene (MUC1) transfected dendritic cells as vaccines: results of a phase 1/11 clinical trial. Cancer Immunol. Immunother. 51 (2002) 669-673
38. Apostolopoulos V., Karanikas V., Haurum J.S., and Mckenzie I.F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer Ag. J. Immunol. 159 (1997) 5211-5218
39. Jerome K.R., Barnd D.L., Bendt K.M., Boyer C.M., Taylor-Papadimitriou J., McKenzie I.F., Bast Jr. R.C., and Finn O.J. CTL-derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51 (1991) 2908-2917
40. Ioannides C.G., Fisk B., Jerome K.R., Irimura T., Wharton J.T., and Finn O.J. CTL from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 151 (1993) 3693-3701
41. Grosso J.F., Herbert L., Owen J.L., and Lopez D.M. MUC1/sec-expressing tumors are rejected in vivo by a T cell-dependent mechanism and secrete high levels of CCL2. J. Immunol. 173 (2004) 1721-1730
42. Wright S.E., Rewers-Felkins K.A., Quinlin I.S., Eldridge P.W., Zorsky P.E., Klug P.P., Phillips C.A., and Philip R. Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int. J. Mol. Med. 9 (2002) 401-404
43. Wright S.E., Kilinski L., Talib S., Lowe K.E., Burnside J.S., Wu J.Y., Dolby N., Dombrowski K.E., Lebkowski J.S., and Philip R. Cytotoxic T Lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J. Immunother. 23 (2002) 2-10
44. Wright S.E., Khaznadar R., Wang Z., Quinlin I.S., Rewers-Felkins K.A., Phillips C.A., and Patel S. Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand. J. Immunol. 67 (2008) 24-29
45. Dobrzanski M.J., Reome J.B., Hylind J.C., and Rewers-Felkins K.L. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and non-differentiated T cell localization, activation and function in progressive breast cancer. J. Immunol. 177 (2006) 8191-8201
46. Burgess S.J., Marusina A.I., Pathmanathan I., Borrego F., and Coligan J.E. IL-21 down-regulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J. Immunol. 176 (2006) 1490-1497
47. Zubkova I., Mostowski H., and Zaitseva M. Up-regulation of IL-7, stromal-derived factor-1 alpha, thymus-expressed chemokine, and secondary lymphoid tissue chemokine gene expression in the stromal cells in response to thymocyte depletion: implication for thymus reconstitution. J. Immunol. 175 (2005) 2321-2330
48. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A., Padera R., Jaklitsch M.T., Shankar S., Chen T.C., Korman A., Allison J.P., and Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. 100 (2003) 4712-4717
49. Zhang Z., Yu Y., Xu F., Berchuck A., van Haaften-Day C., Havrilesky L.J., de Bruijn H.W., van der Zee A.G., Woolas R.P., Jacobs I.J., Skates S., Chan D.W., and Bast Jr. R.C. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol. Oncol. 107 (2007) 526-531
50. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006) 610-621
51. Mantovani A., Bonecchi R., and Locati M. Turning inflammation and immunity by chemokine sequestration: decoys and more. Nat. Rev. Immunol. 6 (2006) 907-918
52. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 4 (2004) 540-550
53. Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B., Chizzolini C., and Dayer J.M. CCR5 is characteristic of Th1 lymphocytes. Nature 391 (1998) 344-345
54. Luther S.A., and Cyster J.G. Chemokines as regulators of T cell differentiation. Nat. Immunol. 2 (2001) 102-107
55. Sallusto F., Lenig D., Mackay C.R., and Lanszavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187 (1998) 875-883
56. Yamamoto J., Adachi Y., Onoue Y., Okabe Y., Itazawa T., Toyoda M., Seki T., Morohashi M., Matsushima K., and Miyawaki T. Differential expression of the chemokine receptors by the Th1 and Th2 type effector populations within the circulating CD4 T cells. J. Leuk. Biol. 68 (2000) 568-574
57. Schwartzentruber D.J., Solomon D., Rosenberg S.A., and Topalian S.L. Characterization of lymphocytes infiltrating human breast cancer: specific immune reactivity detected by measuring cytokine secretion. J. Immunother. 12 (1992) 1-12
58. Sakaguchi S. Naturally arising Foxp3-expressing CD25/CD4 regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6 (2005) 345-352
59. Paust S., Lu L., McCarty N., and Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc. Natl. Acad. Sci., U.S.A. 101 (2004) 10398-10403
60. Fallarino F., Grohmann U., Woo K., Hwang K., Orabona C., Vacca C., Bianchi R., Belladonna M.L., Fioretti M.L., Alegre, and Puccetti P. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4 (2003) 1206-1212
61. Munn D.H., Sharma M.D., and Mellor A.L. Ligation of B7-1/B7-2 by human CD4 T cells triggers indoleamine 2,3-dioxgenase activity in dendritic cells. J. Immunol. 172 (2004) 4100-4110
62. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 (2001) 823-832
63. Tran D.Q., Ramsey H., and Shevach E.M. Induction of FOXP3 expression in naïve human CD4+FOXP3- T cells by T cell receptor stimulation is TGF{beta}-dependent but does not confer a regulatory phenotype. Blood 110 (2007) 2983-2990
64. Brusko T.M., Putnam A.L., and Bluestone J.A. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol. Revs. 223 (2008) 371-390
65. Hill J.A., Feuerer M., Tash K., Haxhinasto S., Perez J., Melamed R., Mathis D., and Benoist C. Foxp3 transcription-factor-dependent and independent regulation of the regulatory T cell transcriptional signature. Immunity 27 (2007) 786-800
66. Collins A.V., Brodie D.W., Gilbert R.J.C., Iaboni A., Manso-Sancho R., Walse B., Stuart D.I., van der Merwe P.A., and Davis S.J. The interaction properties of co-stimulatory molecules revisited. Immunity 17 (2002) 201-210
67. Zheng Y., Manzotti C.N., Liu M., Burke F., Mead K.I., and Sansom D.M. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J. Immunol. 172 (2004) 2778-2784
68. Quezada S.A., Peggs K.S., Curran M.A., and Allison J.P. CTLA-4 blockade and GM-CSF combination immunotherapy alters the intra-tumor balance of effector and regulatory T cells. J. Clin. Invest. 116 (2006) 1935-1945
69. Vukmanovic-Stejic M., Zhang Y., Cook J.E., Fletcher J.M., McQuaid A., Masters J.E., Rustin M.H.A., Taams L.S., Beverley P.C.L., Macallan D.C., and Akbar A.N. Human CD4CD25hiFoxp3 regulatory T cells are derived by rapid turn over of memory populations in vivo. J. Clin. Invest. 116 (2006) 2423-2433
70. Beyer M., Kochanek M., Giese T., Endl E., Weihrauch M.R., Knolle M.P.A., Classen S., and Schultze J.L. In vivo peripheral expansion of naïve CD4CD25high Foxp3 regulatory T cells in patients with multiple myeloma. Blood 107 (2006) 3940-3949
71. Hoffmann P., Eder R., Boeld T.J., Doser K., Piseshka B., Andreesen R., and Edinger M. Only the CD45RA subpopulation of CD4CD25high T cells gives rise to homogeneous regulatory T cell lines upon in vitro expansion. Blood 108 (2006) 4260-4267
72. Taub D.D., Conlon K., Lloyd A.R., Openheim J.J., and Kelvin D.J. Preferential migration of activated CD4 and CD8 T cells in response to MIP-1alpha and MIP-1beta. Science 260 (1993) 355-358
73. Osterwegel M.A., Mandelbrot D.A., Boyd S.D., Lorbach R.B., Jarrett D.Y., Abbas A.K., and Sharpe A.H. The role of CTLA-4 in regulating Th2 differentiation. J. Immunol. 163 (1999) 2634-2642
74. Anderson D., Bieganowska K.D., Bar-Or A., Oliverira E.M., Carreno B., Collins M., and Hafler D.A. Paradoxical inhibition of T cell function in response to CTLA-4 blockade: heterogeneity within the human T cell population. Nat. Med. 6 (2000) 211-218
75. Kato T., and Nariuchi H. Polarization of naïve CD4 T cells toward the Th1 subset by CTLA-4 co-stimulation. J. Immunol. 164 (2000) 3554-3563
76. Alegre M.L., Shiels H., Thompson C.B., and Gajewski T.F. Expression and function of CTLA-4 in Th1 and Th2 cells. J. Immunol. 161 (1998) 3347-3348
77. Walunas T.L., and Bluestone J.A. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J. Immunol. 160 (1998) 3855-3864
78. Dunn G.P., Koebel C.M., and Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat. Revs. Immunology 6 (2006) 836-848
79. + regulatory T cells in antitumor immune response. J. Immunol. 175 (2005) 4433-4440
80. Wang Z., Hong J., Sun W., Xu G., Li N., Chen X., Liu A., Xu A.L., Sun B., and Zhang J.Z. Role of IFN-γ in induction of Foxp3 and conversion of CD4+CD25- T cells to CD4 Tregs. J. Clin. Invest. 116 (2006) 2434-2441
81. Lizee G., Radvanyi L.G., Overwijk W.W., and Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin. Cancer Res. 12 (2006) 4794-4803
82. Ghiringhelli F., Menard C., Puig P., Ladoire S., Roux S., Martin F., Solary E., Le Cesne A., Zitvogel L., and Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4/CD25 regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56 (2007) 641-648
83. Colombo M.P., and Piconese S. Regulatory T cell-inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer 7 (2007) 880-887
84. Mahnke K., Schonfeld K., Fondel S., Ring S., Karakhanova S., Wiedemeyer K., Bedke T., Johnson T.S., Storn V., Schallenberg S., and Enk A.H. Depletion of CD4/CD25 human regulatory T cells in vivo: kinetics of TReg depletion and alteration in immune functions in vivo and in vitro. Int. J. Cancer 120 (2007) 2723-2733
85. Dannull J., Su Z., Rizzieri D., Yang B.K., Coleman D., Yancey D., Zhang A., Dahm P., Chao N., Gilboa E., and Vieweg J. Enhancement of vaccine mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115 (2005) 3623-3633